- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01487330
First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System (SJM TAVI FIH)
First In Human Experience and Assessment of the 23mm SJM Transcatheter Aortic Valve Implant and the SJM TAVI Transfemoral Delivery System (SJM TAVI FIH)
The purpose of this first-in-human study is to assess the technical feasibility, deployment characteristics, and safety of the 23mm SJM Transfemoral Transcatheter Heart Valve and delivery system in subjects with severe symptomatic aortic stenosis (AS).
This is a single center, prospective, non-randomized, first-in-human investigational study without concurrent or matched controls.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Belfast, Storbritannien
- Royal Victoria Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Written Informed Consent for participation prior to procedure.
- Legal age in host country.
- Aortic annulus 19-21mm diameter
- Senile degenerative aortic stenosis with derived mean gradient >40mmHg or jet velocity greater than 4.0 m/s or an initial valve area of <1.0 cm2 (or aortic valve area index ≤ 0.6 cm2/m2)
- NYHA Functional Classification of II or greater.
- Predicted operative mortality or serious, irreversible morbidity risk is <50% at 30 days.
- Suitable peripheral vessels and aorta to allow for access of the 18 French delivery system.
Exclusion Criteria:
- History of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months (≤180 days) of index procedure.
- Carotid artery disease requiring intervention.
- Myocardial infarction (MI) within 6 months (≤180 days) of the index procedure.
- Native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
- Mitral or tricuspid valvular regurgitation (grade II) or moderate to severe mitral stenosis.
- Aortic root angulation >70 degrees (horizontal aorta).
- Pre-existing prosthetic valve or prosthetic ring in any position. LVEF < 20%.
- Untreated coronary artery disease (CAD) requiring revascularization.
- Severe basal septal hypertrophy.
- Percutaneous interventional or other invasive cardiac or peripheral procedure ≤ 14 days or history of previous endocarditis.
- Uncontrolled atrial fibrillation (AF) or is in chronic AF without long term oral anticoagulation.
- Evidence of intracardiac mass, thrombus, or vegetation.
- Hemodynamic instability
- Significant pulmonary disease.
- Nonreactive pulmonary hypertension.
- Chronic steroid use.
- Hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
- Renal insufficiency as evidenced by a serum creatinine > 3.0 or end-stage renal disease requiring chronic dialysis.
- Morbid obesity defined as BMI ≥ 35.
- Subject's iliac arteries have severe calcification, tortuosity, diameter <6mm, or subject has had an aorto-femoral bypass.
- Ongoing infection or sepsis.
- Blood dyscrasias
- Significant aortic disease.
- Pre-existing endovascular stent graft in the supra- or infrarenal aorta or pre-existing stent grafts in the ileo-femoral arteries.
- Active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months (≤ 90 days) prior to the index procedure.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Subjects receiving TAVI valve
|
Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Assessment of Technical Feasibility and Device Deployment Characteristics
Tidsram: At time of procedure
|
Evaluate the technical feasibility and device deployment characteristics (observed at procedure) by:
|
At time of procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Quantification of SAEs Reported (Device Related or Procedure Related)
Tidsram: Through 12 months post implantation
|
Evaluate the safety of the 23mm SJM Transcatheter Aortic Heart Valve and transfemoral delivery system by:
|
Through 12 months post implantation
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Ganesh Manoharan, MD, Royal Victoria Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1103
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .